Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
MXCT
Upturn stock ratingUpturn stock rating

MaxCyte Inc (MXCT)

Upturn stock ratingUpturn stock rating
$1.39
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

08/28/2025: MXCT (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

6 Analysts rated it

Limited analyst coverage, niche firm, research info may be scarce.

1 Year Target Price $6.68

1 Year Target Price $6.68

Analysts Price Target For last 52 week
$6.68 Target price
52w Low $1.26
Current$1.39
52w High $5.2

Analysis of Past Performance

Type Stock
Historic Profit -21.82%
Avg. Invested days 27
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 2.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 08/28/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 148.18M USD
Price to earnings Ratio -
1Y Target Price 6.68
Price to earnings Ratio -
1Y Target Price 6.68
Volume (30-day avg) 6
Beta 0.27
52 Weeks Range 1.26 - 5.20
Updated Date 08/29/2025
52 Weeks Range 1.26 - 5.20
Updated Date 08/29/2025
Dividends yield (FY) -
Basic EPS (TTM) -0.42

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Revenue by Geography

Earnings Date

Report Date 2025-08-06
When -
Estimate -0.1
Actual -0.12

Profitability

Profit Margin -125.22%
Operating Margin (TTM) -167.24%

Management Effectiveness

Return on Assets (TTM) -14.19%
Return on Equity (TTM) -21.74%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 40128240
Price to Sales(TTM) 4.14
Enterprise Value 40128240
Price to Sales(TTM) 4.14
Enterprise Value to Revenue 1.12
Enterprise Value to EBITDA -11.07
Shares Outstanding 106607000
Shares Floating 96174121
Shares Outstanding 106607000
Shares Floating 96174121
Percent Insiders 1.78
Percent Institutions 75.31

ai summary icon Upturn AI SWOT

MaxCyte Inc

stock logo

Company Overview

overview logo History and Background

MaxCyte, Inc. was founded in 1998 and is headquartered in Gaithersburg, Maryland. It is a global cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research, development, and commercialization of novel cell therapies.

business area logo Core Business Areas

  • Cell Engineering Platform: MaxCyte's core technology centers around its flow electroporation platform, enabling complex cell engineering to support the discovery, development, manufacturing and commercialization of a new generation of cell-based medicines.
  • Partnerships: MaxCyte partners with biopharmaceutical companies to enable their cell therapy programs and receives licensing fees, milestone payments, and royalties based on the clinical and commercial success of their partners' programs.

leadership logo Leadership and Structure

MaxCyte is led by a board of directors and a management team. The CEO is Maarten Persoon. The organizational structure includes departments focused on research, development, manufacturing, commercial operations, and finance.

Top Products and Market Share

overview logo Key Offerings

  • ExPERT platform: The ExPERT platform is MaxCyte's core technology. It enables the delivery of a broad range of molecules, including DNA, RNA, CRISPR/Cas9 ribonucleoproteins, and proteins, into cells with high efficiency and viability. Competitors include Lonza, Thermo Fisher Scientific, and Miltenyi Biotec. MaxCyte generates revenue from instrument sales, cell processing assemblies (CPAs), and service contracts.

Market Dynamics

industry overview logo Industry Overview

The cell therapy market is rapidly growing, driven by advancements in immunotherapy, gene editing, and regenerative medicine. There is a high demand for cell engineering technologies to develop and manufacture cell therapies.

Positioning

MaxCyte is a leading provider of cell engineering technology in the cell therapy market. Its flow electroporation platform offers several advantages, including high efficiency, scalability, and versatility.

Total Addressable Market (TAM)

The total addressable market is estimated to be billions of dollars. MaxCyte is positioned to capture a significant share of the market through its strategic partnerships and continued innovation.

Upturn SWOT Analysis

Strengths

  • Proprietary flow electroporation technology
  • Strong partnerships with leading biopharmaceutical companies
  • Scalable and versatile platform
  • Experienced management team

Weaknesses

  • Dependence on partner programs for revenue
  • Limited number of commercialized products
  • High operating expenses
  • Susceptible to changes in regulatory environment for cell therapies

Opportunities

  • Expansion of partnerships
  • Development of new cell therapy applications
  • Geographic expansion
  • Acquisitions

Threats

  • Competition from other cell engineering technologies
  • Regulatory hurdles
  • Clinical trial failures of partner programs
  • Economic downturns

Competitors and Market Share

competitor logo Key Competitors

  • LONZA.SW
  • TMO
  • MILT.DE

Competitive Landscape

MaxCyte's competitive advantage lies in its proprietary flow electroporation technology, which enables high efficiency and scalability. However, it faces competition from other cell engineering technologies, such as viral transduction and lipofection.

Growth Trajectory and Initiatives

Historical Growth: MaxCyte's historical growth has been driven by its increasing number of partnerships and the clinical progress of its partners' programs.

Future Projections: Future growth projections are dependent on the progress of ongoing clinical trials and new partnerships. Analyst estimates can be found in financial reports.

Recent Initiatives: Recent strategic initiatives include expansion of manufacturing capacity, new partnerships, and development of new cell therapy applications.

Summary

MaxCyte is a cell engineering company with a proprietary platform and partnerships with biopharmaceutical companies. Its success depends on the clinical progress of partner programs. It needs to expand its number of approved products, as revenues largely depend on companies who have approved the technology. Its strength lies in its unique technology that could lead to better clinical solutions.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • MaxCyte Investor Relations
  • SEC Filings
  • Analyst Reports
  • Industry Reports

Disclaimers:

The data and analysis provided are for informational purposes only and should not be considered investment advice. The information is based on available data and analysis and is subject to change. Consult with a qualified financial advisor before making any investment decisions.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About MaxCyte Inc

Exchange NASDAQ
Headquaters Rockville, MD, United States
IPO Launch date 2021-07-30
President, CEO & Executive Director Mr. Maher Masoud
Sector Healthcare
Industry Medical Devices
Full time employees 114
Full time employees 114

MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. It also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.